Swiss army knife maker Victorinox considers production shift to ease US tariffs
"We are looking into carrying out directly on site individual processing steps at the end of the value chain, such as the final cleaning and packaging of commercial knives," CEO Carl Elsener said in an interview published today.
"That would reduce the value of the goods on which we have to pay customs duty by 10% to 15%," he added.
Switzerland has been particularly hard hit by Washington's trade policy under President Donald Trump, who earlier this month ratcheted up US tariffs on Swiss imports to 39%.
The US is an important market for Swiss machinery, watches and chocolate.
Victorinox, which makes commercial knives as well as its well-known pocket knives, generates some 13% of its revenue in the country.
Elsener told WirtschaftsWoche the customs duties were coming at an already difficult time.
"The strong Swiss franc has put our competitiveness and our margins under considerable pressure," Elsener said.
Still, high inventories in the US meant the tariffs would not affect Victorinox until early next year, he added. For now, the firm would wait and see how things develop, he said.
Economic uncertainty caused by Trump's trade policies has fueled demand for the safe haven Swiss franc, boosting the currency and making Swiss-made goods dearer abroad.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Agriland
33 minutes ago
- Agriland
Annual global milk supply now forecast to grow by 1.4%
The global dairy outlook has improved with annual milk supply likely to expand by 1.4% this year, according to a new report from Ornua. The latest Ornua Global Dairy Market Report outlines that this increase will be driven largely by growth in the US. European milk supply is expected to grow by +0.5% annually, however the report warns this could be affected by weather or animal health issues. Globally, milk collections increased by 2.1% in June, boosted by flows in the US where collections rose by 3.3%. While bird flu affected last year's output for American farmers, the report outlined that supply is strong and should expand in the second half of the year. Across European Union member states (EU-27) collections rose marginally in June by 0.2%, while in May they were up 0.5%. In Ireland, Ornua said that flows lifted sharply in recent months against a low base and grew again in June by nearly 5%. German saw milk collections drop by 1.6% in May and by a further 2.1% in June. Collections increased in France across May and June, but the report highlights that weekly flows weakened in July. While flows dropped in The Netherlands, Ornua said there should be a positive change there compared to a low base. Output was strong in Poland during quarter two and lifted by 1.9% in June. The report notes that UK flows have been strong in recent months with output increasing by 5.8% in May and 6.5% in June. In New Zealand, where peak season has passed, milk flows lifted sharply in June albeit against a weak base. Ornua said that favourable milk prices and pasture conditions means growth could exceed expectations. In Argentina, improving farmgate prices and favourable weather supported an increase in milk flows. The report added that milk production is forecast to drop in China this year due to lower farmgate prices. Following last month's trade agreement between the European Union and the US, a baseline 15% tariff or most-favored nation (MFN) rate (whichever is higher) will apply to EU dairy exports to the US. Ornua said that butter and cheese will benefit from this change, but casein will see a rate of 15% (from 0% before April 2025). "This should provide clarity after a period of uncertainty and interest usually returns in September after the holiday period. Indeed, there are tentative signs of price stability. "However, most European commodities still command a premium. Against a backdrop of volatile global trade and geopolitical environment, this may dampen demand later in the year," the report added.
Irish Examiner
7 hours ago
- Irish Examiner
Profits down at Novartis Ireland to €8.4m as firm ups R&D spend
Pre-tax profits at the Irish arm of Swiss-headquartered pharmaceutical giant, Novartis, last year declined by 25% to €8m as the company increased its R&D spend. New accounts filed by Novartis Ireland Ltd show that the company recorded the drop in pre-tax profits as revenues declined by 10% from €268.3m to €242.3m. Novartis Ireland is a significant employer in the healthcare industry here with over 1,000 employed in Dublin. The accounts show that revenues from the sale of goods declined from €139.86m to €137.55m while revenues from supply of business services decreased from €128.46m to €104.77m. The directors state that revenues declining in pharma products sales were due to price and volume erosion of mature products. Turnover relating to Novartis Corporate Centre (NOCC) services decreased by 18% driven primarily by the reduction in functions related to Novartis's global initiative which launched in 2022 targeting a more focused pharmaceutical offering. The company has a significant R&D arm in Ireland with numbers employed in R&D last year increasing from 224 to 270. Last year, Novartis Ireland increased the R&D spend rising from €26.4m to €34.9m and the company booked an R&D credit of €4.5m in the profit and loss account. Overall numbers employed at Novartis Ireland Ltd reduced from 1,024 to 1,010 last year and the company also employed 663 in 'general and administration', 72 in marketing, sales and distribution and five in production and supply. Staff costs last year declined from €138.8m to €123.98m that included €95.5m in wages and salaries and €4.7m in share-based payments. Directors' pay increased from €992,000 to €1.35m made up of €1.27m in emoluments and €76,000 in pension contributions. They said: 'We have combined our former Novartis Technical Operations and Customer and Technology Solutions units to create a new operations unit called operations. This new unit seeks to provide a stronger and simpler operational backbone that can accelerate multiple technology transformation initiatives more efficiently, create novel digital solutions at scale, and increase productivity, while maintaining industry-leading quality and service levels." During the year, the company launched two new medicines aimed at tackling cancer, Luxturna and Leqvio. Under the heading of patient expiration and product competition, the directors said: 'The Irish government continues to closely monitor pharmaceutical pricing and profitability, with pressure to control spending on HSE medicines.' They state that the company 'manages these risks by having a strong pipeline, ensuring that it brings innovative products to market and using competitive pricing strategies while closely monitoring costs'. Shareholder funds totalled €88.8m that included accumulated profits of €51.9m.
RTÉ News
a day ago
- RTÉ News
Swiss army knife maker Victorinox considers production shift to ease US tariffs
Victorinox, the maker of Swiss army knives, is considering moving part of its production to the US to lessen the impact of import tariffs on its business, the company's CEO told German business magazine WirtschaftsWoche. "We are looking into carrying out directly on site individual processing steps at the end of the value chain, such as the final cleaning and packaging of commercial knives," CEO Carl Elsener said in an interview published today. "That would reduce the value of the goods on which we have to pay customs duty by 10% to 15%," he added. Switzerland has been particularly hard hit by Washington's trade policy under President Donald Trump, who earlier this month ratcheted up US tariffs on Swiss imports to 39%. The US is an important market for Swiss machinery, watches and chocolate. Victorinox, which makes commercial knives as well as its well-known pocket knives, generates some 13% of its revenue in the country. Elsener told WirtschaftsWoche the customs duties were coming at an already difficult time. "The strong Swiss franc has put our competitiveness and our margins under considerable pressure," Elsener said. Still, high inventories in the US meant the tariffs would not affect Victorinox until early next year, he added. For now, the firm would wait and see how things develop, he said. Economic uncertainty caused by Trump's trade policies has fueled demand for the safe haven Swiss franc, boosting the currency and making Swiss-made goods dearer abroad.
